Frontiers in Cardiovascular Medicine (Jan 2024)

Effect of sacubitril/valsartan on sinus rhythm maintenance after catheter ablation in patients with persistent atrial fibrillation without reduced ejection fraction heart failure: a study protocol for a multi-center, open-label, randomized, controlled, superiority clinical trial

  • Ruowu Qiu,
  • Ruowu Qiu,
  • Qingqing Ni,
  • Qingqing Ni,
  • Muli Wu,
  • Muli Wu,
  • Zhongbo Xiao,
  • Zhongbo Xiao,
  • Jiaxin Xiao,
  • Jiaxin Xiao,
  • Weizhao Lin,
  • Weipeng Huang,
  • Yequn Chen,
  • Yequn Chen,
  • Chang Chen,
  • Chang Chen,
  • Liekai Hong,
  • Liekai Hong,
  • Liekai Hong

DOI
https://doi.org/10.3389/fcvm.2024.1303540
Journal volume & issue
Vol. 11

Abstract

Read online

IntroductionA high recurrence rate of atrial fibrillation was monitored after catheter ablation for persistent atrial fibrillation. Sacubitril/valsartan can improve outcomes for patients with heart failure and ventricular tachycardia, but few studies examined whether it can reduce recurrence or improve cardiovascular outcomes in patients with persistent atrial fibrillation after catheter ablation. In this study, we will assess the effect of sacubitril/valsartan on sinus rhythm maintenance and incidence of major adverse cardiovascular events (MACE) in patients with persistent atrial fibrillation after catheter ablation through a randomized controlled trial (RCT).MethodsThis is a multi-center, randomized, controlled, open-label, superiority clinical trial involving 462 patients without reduced ejection fraction heart failure after catheter ablation of persistent atrial fibrillation. Patients will be randomized to (1) receive the standard treatment strategy plus sacubitril/valsartan titration, or (2) receive the standard treatment strategy without taking sacubitril/valsartan. The primary outcome will be sinus rhythm maintenance rate over 12 months, monitored by random electrocardiogram and 24-h Holter electrocardiogram.DiscussionThis study is designed to evaluate the effect of sacubitril/valsartan on sinus rhythm maintenance and incidence of major adverse cardiovascular events (MACE) in patients with persistent atrial fibrillation after catheter ablation. The results will evaluate sacubitril/valsartan as a novel treatment for improving prognosis and a complement to conventional drug therapy. Trial RegistrationRegistered with Chinese Clinical Trials Registry on 27 August 2022, identifier: ChiCTR2200062995.

Keywords